SYNB8802 / Synlogic - LARVOL DELTA

Safety and Tolerability of SYNB8802 in Healthy Adult Volunteers and Adult Subjects With Enteric Hyperoxaluria (clinicaltrials.gov) - P1 | N=77 | Completed | Sponsor: Synlogic | Recruiting ➔ Completed

Trial completion • Nephrology

SYNB8802 Lowers Urinary Oxalate During a Diet-Controlled Study in Patients with Roux-en-Y Gastric Bypass (KIDNEY WEEK 2023) - "SYNB8802 was well tolerated in patients with RnY gastric bypass and demonstrated the capacity to lower UOx. SYNB8802 should be further evaluated in subjects afflicted with kidney stone disease and EH."

Bariatric surgery • Clinical • Gastrointestinal Disorder • Nephrology • Renal Calculi

Safety, Tolerability, and Pharmacodynamics of SYNB8802v1 in Subjects With History of Gastric Bypass Surgery or Short-bowel Syndrome (clinicaltrials.gov) - P1 | N=11 | Completed | Sponsor: Synlogic | Recruiting ➔ Completed

Bariatric surgery • Surgery • Trial completion • Gastrointestinal Disorder • Nephrology • Short Bowel Syndrome • CD4

Robust performance of a live bacterial therapeutic chassis lacking the colibactin gene cluster. (PubMed, PLoS One) - "Deletion of pks also had no effect on the activity of strains engineered to degrade phenylalanine (SYNB1618 and SYNB1934) or oxalate (SYNB8802). Importantly, there was no significant difference on in vivo strain performance between the clinical-stage strain SYNB1934 and its isogenic Δpks variant with regards to recovery of the quantitative strain-specific biomarkers d5- trans-cinnamic acid, and d5-hippuric acid. Taken together, these data support that the pks island is dispensable for Synthetic Biotic fitness and activity in vivo and that its removal from engineered strains of EcN will not have a deleterious effect on strain efficacy."

Journal • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

Safety, Tolerability, and Pharmacodynamics of SYNB8802v1 in Subjects With History of Gastric Bypass Surgery or Short-bowel Syndrome (clinicaltrials.gov) - P1 | N=10 | Recruiting | Sponsor: Synlogic

New P1 trial • Gastrointestinal Disorder • Nephrology • Short Bowel Syndrome • CD4